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Abstract
Originally described by Brock and Teare, today hypertrophic cardiomyopathy is clinically defined
as left (or right) ventricular hypertrophy without a known cardiac or systemic cause, such as
systemic hypertension, Fabry's disease or aortic stenosis.
Also appreciated today is the enormous genotypic and phenotypic heterogeneity of this disease
with more than 300 mutations over more than 24 genes, encoding various sarcomeric,
mitochondrial and calcium-handling proteins, all as genetic causes for hypertrophic
cardiomyopathy.
Phenotypically, the disease can vary from negligible to extreme hypertrophy, affecting either the
left and/or right ventricle in an apical, midventricular or subaortic location.
Left ventricular false tendons are thin, fibrous or fibromuscular structures that traverse the left
ventricular cavity. Recently, a case report was presented where it was shown that such a false
tendon, originating from a subaortic location, was responsible for striking ST-segment elevation on
the surface electrocardiogram.
In this case report, a case is presented where such a subaortic tendon led to the classic
echocardiographic appearance of hypertrophic cardiomyopathy, thus in the assessment of
hypertrophic cardiomyopathy, this entity needs to be excluded in order to prevent a false positive
diagnosis of hypertrophic cardiomyopathy.
Introduction
Hypertrophic cardiomyopathy (HCM) was first described
in 2 publications between 1957–1959 by Brock [1-3].
During this period Teare [1,4] also described the entity of
asymmetrical septal hypertrophy in 8 autopsy cases.
HCM is the most prevalent genetic cardiovascular disease,
as it affects one in 500 individuals and exhibits enormous
genotypic and phenotypic heterogeneity [5].
Phenotypically, hypertrophy can vary from negligible to
extreme – similarly fibrosis and myocyte disarray can also
range from negligible to extreme [5]. This phenotypic var-
iation is the result of the vast array of mutations present in
the family of HCM [5].
These mutations can be inherited (familial) or can occur
de novo (sporadic) [6].
Currently, more than 300 mutations, which are scattered
over more than 24 genes are known as causes for HCM
[5]. These involved genes encode various proteins of the
sarcomere, mitochondria and the calcium-handling appa-
ratus [5]. Sarcomeric mutations can affect the thick myo-
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filament (beta-myosin heavy chain, regulatory myosin
light chain and essential myosin light chain), the interme-
diate myofilament (myosin binding protein C) or the thin
myofilament (cardiac troponins T and I, alpha-tropomy-
osin and actin) [5].
It is thus no wonder that the clinical presentation can
range from apical hypertrophy, mid-ventricular hypertro-
phy, concentric hypertrophy and subaortic hypertrophy
of the left and/or right ventricle [1,5-10].
Of all these variants, hypertrophic obstructive cardiomy-
opathy (HOCM) is the variant that has been studied the
most [8]. In this entity (previously known as idiopathic,
hypertrophic, subaortic stenosis) asymmetrical, septal
hypertrophy is accompanied by the following three ele-
ments [8]: systolic anterior motion (SAM) of the anterior
leaflet of the mitral valve; a left ventricular outflow tract
(LVOT) gradient and mitral regurgitation.
Left ventricular false tendons are thin, fibrous or fibro-
muscular structures that traverse the left ventricular cavity
and they may be single or multiple [11]. Recently, it was
demonstrated that such a left ventricular false tendon,
attached to the subaortic portion of the interventricular
septum, led to striking ST-segment elevation on the sur-
face electrocardiogram [12]. In this case report another
possible diagnostic pitfall that can arise due to the pres-
ence of a subaortic tendon is presented.
Case report
A case report is presented where it is shown that a left ven-
tricular false tendon, when attached to the subaortic por-
tion of the interventricular septum – a subaortic tendon –
can mimic the echocardiographic appearance of hyper-
trophic cardiomyopathy.
A 30-year old Caucasian male was referred for a cardiovas-
cular examination by his primary care physician. The clin-
ical reason for the referral was the presence of a soft,
subaortic midsystolic murmur (Levine grade I). The
patient was totally asymptomatic and no previous medi-
cal or surgical problems were present. Clinical examina-
tion confirmed the grade I, subaortic, midsystolic
murmur. The rest of the clinical examination was normal.
Echocardiography demonstrated a classical parasternal
long axis picture of hypertrophic cardiomyopathy, with
the phenotype of subaortic hypertrophy (see additional
file 1, 2, 3 and 4). However, no systolic anterior motion of
the mitral valve (SAM) and no left ventricular outflow
tract gradient were present.
However, further examination revealed the presence of a
big, muscular, subaortic tendon, running parallel to the
interventricular septum and giving the false impression of
hypertrophic cardiomyopathy. See additional file 2 dem-
onstrating this muscular tendon clearly as a separate struc-
ture.
Discussion
The echocardiographic assessment of ventricular hyper-
trophy is an extremely important component of the cardi-
ovascular examination and it is also one of the most
difficult clinical scenario's because of the vast array of
pathologies, each one with a different prognosis.
Shapiro et al [13] performed a prospective, echocardio-
graphic examination to determine the prevalence of local-
ized, subaortic hypertrophy in 1000 consecutive patients
presenting for a routine echocardiographic examination.
They excluded patients with hypertrophic cardiomyopa-
thy and 8 cases of such localized, subaortic hypertrophy
were found. In their series, localized subaortic hypertro-
phy was diagnosed when the subaortic septum was 50%
thicker than the mid-point of the septum.
Numerous diseases can lead to secondary left ventricular
hypertrophy, which may then imitate hypertrophic cardi-
omyopathy [14] Jategaonkar et al described a case of
HCM, with all the components of HOCM – asymmetric
septal hypertrophy, SAM and mitral regurgitation – which
turned out to be all due to an underlying pheochromocy-
toma [14]. Another important condition to exclude when
localized, subaortic hypertrophy is found is hyperparath-
yroidism, as it has been shown that this condition is
another important mimic of hypertrophic cardiomyopa-
thy [15]. In the analysis of so-called "hypertrophic cardiac
syndromes", they are often distinguished from one
another by features such as: valvular abnormalities, out-
flow tract obstruction, electrocardiographic patterns, the
presence or absence of diastolic dysfunction, as well as the
degree and pattern of ventricular hypertrophy [16].
Amyloidosis causes the accumulation of amyloid in the
myocardial interstitium and this process ultimately leads
to a ventricle with a firm, rubbery consistency and ven-
tricular hypertrophy [16]. Two-dimensional strain is a
unique imaging mode that permits the objective analysis
of myocardial motion throughout the entire cardiac cycle
[16]. Sun et al [16] studied the ability of two-dimensional
strain to assess global and regional function in patients
with amyloidosis, hypertrophic cardiomyopathy and
hypertrophy due to hypertension. They were able to dem-
onstrate that patients with "amyloid cardiomyopathy"
had significantly lower myocardial deformation as seen
by two-dimensional strain imaging than patients with
hypertrophic cardiomyopathy and hypertensive hypertro-
phy. Thus, two-dimensional strain imaging can be addedCardiovascular Ultrasound 2009, 7:31 http://www.cardiovascularultrasound.com/content/7/1/31
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to the armamentarium of the echocardiographer in the
assessment of idiopathic ventricular hypertrophy.
Another good example of how a meticulous echocardio-
graphic examination can detect the presence of a specific
and unusual cause for severe ventricular hypertrophy, is
Fabry's disease – an X-linked metabolic storage disease
where glycosphingolipid accumulates in the myocardium
and other tissues, due to deficient activity of the enzyme
alpha-galactosidase A [17]. The endocardium in Fabry's
cardiomyopathy has a peculiar binary appearance, detect-
able by transthoracic echocardiography [17].
Thus, it is clear that not all cases of subaortic hypertrophy
are due to hypertrophic cardiomyopathy.
This case report adds another mimic of hypertrophic car-
diomyopathy to the list – that of the muscular subaortic
tendon.
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Additional file 1
Parasternal long axis view. This is a movie clip, demonstrating the clas-
sical echocardiographic picture of the subaortic hypertrophy variant of 
hypertrophic cardiomyopathy (HCM).
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-7-31-S1.avi]
Additional file 2
Closer view of subaortic tendon. This is a closer view of the basal inter-
ventricular septum. The thick, muscular subaortic tendon is clearly visible 
as a separate structure, giving the initial impression of hypertrophic cardi-
omyopathy.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-7-31-S2.bmp]
Additional file 3
Parasternal long axis view. Another movie clip, once again from the par-
asternal long axis view, demonstrating the subaortic hypertrophy.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-7-31-S3.wpl]
Additional file 4
Subaortic hypertrophy. Note the appearance of severe, subaortic hyper-
trophy.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1476-
7120-7-31-S4.bmp]